

**MANAGEMENT PLAN FOLLOWING INITIATION OF DIRECT ORAL ANTICOAGULANTS (DOACs)
APIXABAN/DABIGATRAN/EDOXYABAN/RIVAROXABAN**

CONSIDERATIONS AT TIME OF INITIATION

- Confirm appropriateness of therapy
- Obtain baseline labs (CBC/LFTs/SCr) and calculate creatinine clearance (CrCl) using Cockcroft-Gault
- Conduct medication review to assess potential for drug interactions (see <https://depts.washington.edu/anticoag>)
- Review indication for therapy and provide education to patient, supplemented by written materials

DOAC MONITORING CHECKLIST

FOR EACH FOLLOWUP VISIT ¹

- Adherence (including Rx refills)
- Thromboembolic events
- Bleeding events/risk factors
- Adverse effects
- Medication review for potentially interacting drugs including ASA and NSAIDs (see <https://depts.washington.edu/anticoag>)
- Reassessment of appropriateness and duration of therapy
- Repeat CBC
- Repeat SCR/Calculate CrCl

¹ Clinical judgment should be used to determine frequency of monitoring based on patient's overall health, compliance, and risk factors

